Clinical Trial Update: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II intravitreal trial evaluating a combination of E10030 (PDGF antagonist) and ranibizumab (VEGF antagonist) for severe ocular Von Hippel-Lindau disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Hippel-lindau Disease

Drugs mentioned

• E10030 (PDGF antagonist)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Von Hippel-Lindau Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-14